Uterine Leiomyoma (Uterine Fibroids) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Uterine Leiomyoma (Uterine Fibroids) – Pipeline Review, H1 2017’, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)

The report reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Uterine Leiomyoma (Uterine Fibroids) therapeutics and enlists all their major and minor projects

The report assesses Uterine Leiomyoma (Uterine Fibroids) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Addex Therapeutics Ltd

Bayer AG

BioSpecifics Technologies Corp

Dongkook Pharmaceutical Co Ltd

Kissei Pharmaceutical Co Ltd

Laboratoire HRA Pharma

Ogeda SA

Repros Therapeutics Inc

Takeda Pharmaceutical Company Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Uterine Leiomyoma (Uterine Fibroids) - Overview

Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Bayer AG

BioSpecifics Technologies Corp

Dongkook Pharmaceutical Co Ltd

Kissei Pharmaceutical Co Ltd

Laboratoire HRA Pharma

Ogeda SA

Repros Therapeutics Inc

Takeda Pharmaceutical Company Ltd

Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles

collagenase clostridium histolyticum - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Endometriosis and Uterine Fibroids - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elagolix sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVE-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLH-2109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relugolix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telapristone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triptorelin biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulipristal acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vilaprisan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPE-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPEA-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects

Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products

Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones

Featured News & Press Releases

Jan 30, 2017: FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex in the Treatment of Uterine Fibroids

Jan 25, 2017: Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Jan 17, 2017: Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

Dec 12, 2016: Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex in the Treatment of Symptomatic Uterine Fibroids

Nov 21, 2016: FIBRISTAL, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment

Nov 14, 2016: Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex Delivered Orally and Vaginally for the Treatment of Uterine Fibroids

Oct 17, 2016: Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City

Oct 13, 2016: Latest clinical data on Bayer mid-stage candidate Vilaprisan to be presented at ASRM

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials

May 31, 2016: BioSpecifics Technologies Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology

May 18, 2016: Repros Reports Positive Clinical Data for Oral Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

Apr 12, 2016: Repros Reports Positive Clinical Data for Vaginal Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids

Dec 21, 2015: Repros Updates Proellex Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by AbbVie Inc, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Addex Therapeutics Ltd, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Bayer AG, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by BioSpecifics Technologies Corp, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Laboratoire HRA Pharma, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Ogeda SA, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Repros Therapeutics Inc, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Dormant Projects, H1 2017

Uterine Leiomyoma (Uterine Fibroids) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports